NCT04532281 is a EARLY_PHASE1 clinical trial of Murine CD19 CAR-T cells in Acute Lymphoblastic Leukemia, sponsored by Zhejiang University.

Who is sponsoring NCT04532281?

NCT04532281 is sponsored by Zhejiang University.

What drugs are being tested in NCT04532281?

Interventions in NCT04532281: Murine CD19 CAR-T cells.

What condition does NCT04532281 study?

NCT04532281 studies Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma of Soft Tissue.

Is NCT04532281 still recruiting?

NCT04532281 is currently recruiting now. Last updated 26 October 2020.

Last reviewed 2020-10-26 · How we verify

NCT04532281

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

Recruiting now EARLY_PHASE1 Last updated 26 October 2020

What this trial tests

EARLY_PHASE1 trial testing Murine CD19 CAR-T cells in Acute Lymphoblastic Leukemia in 120 participants. Currently enrolling.

Timeline

1 November 2020

Primary endpoint
1 November 2023

1 November 2026

Quick facts

Lead sponsor	Zhejiang University
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	1 November 2020
Primary completion	1 November 2023
Estimated completion	1 November 2026
Sites	1 location across China

Drugs / interventions tested

Murine CD19 CAR-T cells — full drug profile →

Conditions studied

Acute Lymphoblastic Leukemia — all drugs for Acute Lymphoblastic Leukemia →
Non-Hodgkin Lymphoma of Soft Tissue — all drugs for Non-Hodgkin Lymphoma of Soft Tissue →

Sponsor

Zhejiang University

Who can join

Eligibility, any sex, with Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma of Soft Tissue. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Study of Murine CD19 CAR-T Cells Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Yin Z, Zhang Y, Wang X. · · 2021 · cited 30× · PMID 34256851 · DOI 10.1186/s40364-021-00309-5
Cancer Stem Cell for Tumor Therapy.
Huang B, Yan X, Li Y. · · 2021 · cited 27× · PMID 34638298 · DOI 10.3390/cancers13194814
CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma.
Ostojska M, Nowak E, Twardowska J, Lejman M, et al · · 2023 · cited 5× · PMID 38003910 · DOI 10.3390/jpm13111595
Sequential allogeneic HSCT after CAR-T therapy for relapsed/refractory acute lymphoblastic leukemia patients: A long-term follow-up result.
Yang T, Dong Y, Shi J, Zhang M, et al · · 2025 · cited 2× · PMID 39947324 · DOI 10.1016/j.jare.2025.02.006
Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy.
Yang TT, Meng Y, Kong DL, Wei GQ, et al · · 2022 · cited 2× · PMID 36110859 · DOI 10.3389/fimmu.2022.934442

Verify or expand the search:

Other recruiting trials for Acute Lymphoblastic Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT05621291 — A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Follo · NA · recruiting
NCT07356154 — A Study of Revumenib and Mezigdomide in People With Leukemia · Phase 1, PHASE2 · recruiting
NCT07479927 — Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Alloge · NA · recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04532281 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 26 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04532281.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing